Antihypertensive therapy: How to evaluate the benefits

Alberto Zanchetti

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

For more than 30 years, the benefits of antihypertensive therapy have been assessed in randomized trials that monitor cardiovascular events. Even greater benefits can result if prevention of (1) congestive heart failure, (2) left ventricular hypertrophy, and (3) progression to more severe hypertension is taken into consideration. However, quantifying the benefits in order to calculate the cost-effectiveness of treatment is not easy. Taking absolute risk and benefit as the only guide to treatment decisions may result in limiting therapy only to elderly hypertensive patients and hypertensive patients with complications. Furthermore, randomized trials, of which the duration is necessarily short, are likely to underestimate treatment benefits. An alternative to such an approach is the actuarial approach: treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained calculated in this way is much lower than the cost calculated from randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches are token into consideration by physicians, patients, politicians, and officers of national health systems.

Original languageEnglish
Pages (from-to)3-8
Number of pages6
JournalThe American Journal of Cardiology
Volume79
Issue number10 A
DOIs
Publication statusPublished - May 22 1997

Fingerprint

Antihypertensive Agents
Therapeutics
Cost-Benefit Analysis
Costs and Cost Analysis
Left Ventricular Hypertrophy
Life Expectancy
Heart Failure
Blood Pressure
Hypertension
Physicians
Health

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antihypertensive therapy : How to evaluate the benefits. / Zanchetti, Alberto.

In: The American Journal of Cardiology, Vol. 79, No. 10 A, 22.05.1997, p. 3-8.

Research output: Contribution to journalArticle

Zanchetti, Alberto. / Antihypertensive therapy : How to evaluate the benefits. In: The American Journal of Cardiology. 1997 ; Vol. 79, No. 10 A. pp. 3-8.
@article{0c4e6d4a9eed4ea98bfe554c6bdea079,
title = "Antihypertensive therapy: How to evaluate the benefits",
abstract = "For more than 30 years, the benefits of antihypertensive therapy have been assessed in randomized trials that monitor cardiovascular events. Even greater benefits can result if prevention of (1) congestive heart failure, (2) left ventricular hypertrophy, and (3) progression to more severe hypertension is taken into consideration. However, quantifying the benefits in order to calculate the cost-effectiveness of treatment is not easy. Taking absolute risk and benefit as the only guide to treatment decisions may result in limiting therapy only to elderly hypertensive patients and hypertensive patients with complications. Furthermore, randomized trials, of which the duration is necessarily short, are likely to underestimate treatment benefits. An alternative to such an approach is the actuarial approach: treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained calculated in this way is much lower than the cost calculated from randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches are token into consideration by physicians, patients, politicians, and officers of national health systems.",
author = "Alberto Zanchetti",
year = "1997",
month = "5",
day = "22",
doi = "10.1016/S0002-9149(97)00264-6",
language = "English",
volume = "79",
pages = "3--8",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10 A",

}

TY - JOUR

T1 - Antihypertensive therapy

T2 - How to evaluate the benefits

AU - Zanchetti, Alberto

PY - 1997/5/22

Y1 - 1997/5/22

N2 - For more than 30 years, the benefits of antihypertensive therapy have been assessed in randomized trials that monitor cardiovascular events. Even greater benefits can result if prevention of (1) congestive heart failure, (2) left ventricular hypertrophy, and (3) progression to more severe hypertension is taken into consideration. However, quantifying the benefits in order to calculate the cost-effectiveness of treatment is not easy. Taking absolute risk and benefit as the only guide to treatment decisions may result in limiting therapy only to elderly hypertensive patients and hypertensive patients with complications. Furthermore, randomized trials, of which the duration is necessarily short, are likely to underestimate treatment benefits. An alternative to such an approach is the actuarial approach: treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained calculated in this way is much lower than the cost calculated from randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches are token into consideration by physicians, patients, politicians, and officers of national health systems.

AB - For more than 30 years, the benefits of antihypertensive therapy have been assessed in randomized trials that monitor cardiovascular events. Even greater benefits can result if prevention of (1) congestive heart failure, (2) left ventricular hypertrophy, and (3) progression to more severe hypertension is taken into consideration. However, quantifying the benefits in order to calculate the cost-effectiveness of treatment is not easy. Taking absolute risk and benefit as the only guide to treatment decisions may result in limiting therapy only to elderly hypertensive patients and hypertensive patients with complications. Furthermore, randomized trials, of which the duration is necessarily short, are likely to underestimate treatment benefits. An alternative to such an approach is the actuarial approach: treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained calculated in this way is much lower than the cost calculated from randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches are token into consideration by physicians, patients, politicians, and officers of national health systems.

UR - http://www.scopus.com/inward/record.url?scp=0030831203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030831203&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(97)00264-6

DO - 10.1016/S0002-9149(97)00264-6

M3 - Article

C2 - 9186060

AN - SCOPUS:0030831203

VL - 79

SP - 3

EP - 8

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10 A

ER -